Iloprost therapy in systemic sclerosis;Iloprosttherapie bei systemischer sklerodermie

Hautarzt

Volumn 54, Issue 9, 2003, Pages 845-851

  Bali, G ^a   Aberer, E ^a  

^a Universitatsklinik fuer Dermatologie und Venerologie Innsbruck   (Austria)

Author keywords

Antifibrotic effect; Iloprost; Infusion Raynaud; Systemic scleroderma

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFIBROTIC AGENT; BOSENTAN; CICAPROST; CYCLOSPORIN A; ILOPROST; NIFEDIPINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; UNIPROST;

DRUG EFFECT; HEMOPERFUSION; HUMAN; PATHOGENESIS; RAYNAUD PHENOMENON; REVIEW; SCORING SYSTEM; SKIN ULCER; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

CONTROLLED CLINICAL TRIALS; FORECASTING; HUMANS; ILOPROST; PLATELET AGGREGATION INHIBITORS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; TIME FACTORS; VASODILATOR AGENTS;

EID: 0042818325     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-003-0578-2     Document Type: Review

References (34)

1. Aigner N, Petje G, Steinboeck G et al. (2001) Treatment of bone-marrow oedema of the talus with the prostacyclin analogue iloprost. J Bone Joint Surg 83-B:855-858
2. Belch J (2000) Therapy of Raynaud's phenomenon and vasculitis. Schering Symposium, Berlin 18.-19.2.2000, S 42-43
3. Belch J, Capell HA, Cooke ED et al. (1995) Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 54:197-200
4. Biasi D, Carletto A, Caramaschi P et al. (1998) Iloprost as cyclic five-day infusions in the treatment of scleroderma. Rev Rhum 65:745-750
5. Ceru S, Pancera P, Sansone S et al. (1997) Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis. Clin Exp Rheumatol 15:381-385
6. Clements PJ, Lanchenbruch PA, Cheng S et al. (1990) Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 33:1256-1263
7. Della Bella S, Molteni M, Mascagni B et al. (1997) Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine. Clin Exp Rheum 15:135-141
8. Della Bella S, Molteni M, Mocellin C et al. (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Lipid Mediators 65:73-83
9. Fagrell B (2000) Iloprost - a stable prostacyclin analogue. Schering Symposium Berlin, 18.-19.2.2000, S 6-8
10. Filaci G, Cutolo M, Scudeletti M et al. (1999) Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. J Rheumatol 38:992-996
11. Gröchenig E (1994) Treatment of frostbite with iloprost. Lancet 344:1152-1153
12. Gröchenig E (2002) Gefäßmedizin. ABW Wissenschafts-verlag Berlin Leiben, S 94-96
13. Kahaleh MB (1994) Raynaud's phenomenon and vascular disease in scleroderma. Curr Opin Rheumatol 6:621-627
14. Keller J, Kaltenecker A, Schricker KT et al. (1984) Behandlung des Raynaud-Phänomens bei Sklerodermie-Patienten mit einem neuen stabilen Prostacyclin-Derivat. Dtsch Med Wochenschr 109:1433-1438
15. LeRoy EC, Krieg T, Black C et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205
16. Lüllmann H, Mohr K (1999) Pharmakologie und Toxikologie, 14. Aufl. Thieme, Stuttgart New York, S 269-272
17. Mazzone A, Mazzucchelli I, Fossati G et al. (1996) Iloprost effects on phagocytes in patients suffering from ischaemic diseases: in vivo evidence for downregulation of αMβ2 integrin. Eur J Clin Invest 26:860-866
18. Mazzone A, Cusa C, Bucci L et al. (1999) The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. Eur J Clin Invest 29:1-5
19. Mazzone A, Cusa C, Mazzucchelli I et al. (1999) Pyoderma gangrenosum complicative ulcerative colitis: an alternative treatment with Iloprost. Current Therapeutic Res 60:357-362
20. Medsger TA, Silman AJ, Steen VD et al. (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159-2167
21. Mittag M, Beckheinrich P, Haustein UF (2001) Systemic sclerosis-related Raynaud's phenomenon: effects of Iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 81:294-297
22. Olschewski H, Walmrath D, Schermuly R et al. (1996) Aerosolised prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124:820-824
23. Olschewski H, Ghofrani A, Schmedl T et al. (2000) Inhaled iloprost to treat severe pulmonary hypertension. Ann Intern Med 132:435-443
24. Rademaker M, Thomas RHM, Provost G et al. (1987) Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J 63:617-620
25. Riemekasten G, Jepsen H, Burmester GR, Hiepe F (1998) Iloprostgabe über 21 Tage als wirksame Therapie bei der progressiven systemischen Sklerodermie - Fallbeschreibung und Literaturübersicht. Z Rheumatol 57:118-124
26. Righi A, Matucci Cerinic M (2002) New treatments in scleroderma: the rheumatologic perspective. JEADV 16:431-432
27. Schuller-Petrovic S (2000) Iloprost in the treatment of venous ulcers. Schering Symposium Berlin 18.-19.2.2000, S 20-21
28. Schulte KL (2000) Dosing alternatives for iloprost in the treatment of peripheral arterial disease (PAD). Schering Symposium Berlin, 18.-19.2.2000, S 12-13
29. Smiley JD (1992) The many faces of scleroderma. Am J Med Sci 304:319-333
30. Stratton R, Shiwen X, Martini G et al. (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108:241-250
31. Tu JH, Eisen AZ (1999) Scleroderma. In: Freedberg IM, Eisen AZ, Wolff K et al. (eds) Dermatology in general medicine, Vol 2, 5th edn. Mc Graw-Hill Inc., New York, pp 2023-2033
32. Wighley FM, Sule SD (2001) Novel therapy in the treatment of scleroderma. Exp Opin Invest Drug 20s 101:31-48
33. Wigley FM, Wise RA, Seibold JR et al. (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. Ann Intern Med 120:199-206
34. Williamson DJ, Wallman L, Jones R et al. (2000) Hemodynamic effects of Bosentan, an endothelin receptor antagonist in patients with pulmonary hypertension. Circulation 102:411-418